Contains Nonbinding Recommendations 

Guidance on Acetaminophen; Caffeine; Dihydrocodeine Bitartrate 

This guidance represents the Food and Drug Administration's (FDA's) current thinking on 
this topic. It does not create or confer any rights for or on any person and does not operate to 
bind FDA or the public. You can use an alternative approach if the approach satisfies the 
requirements of the applicable statutes and regulations. If you want to discuss an alternative 
approach, contact the Office of Generic Drugs. 

Active ingredient: Acetaminophen; Caffeine; Dihydrocodeine Bitartrate 

Form/Route: Tablets/Oral 

Recommended studies: 

Acetaminophen; Caffeine: Dihydrocodeine bitartrate Tablets are a DESI1 effective drug for 
which there are no known or suspected bioequivalence problems, and as such is rated “AA” in 
the FDA/CDER’s Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange 
Book”). 

Analytes to measure (in appropriate biological fluid): Not Applicable 

Bioequivalence based on (90% CI): Not Applicable 

Waiver request of in-vivo testing: 712.8 mg/60 mg/32 mg, and 356.4 mg/30 mg/16 mg 
pursuant to 21 CFR 320.22 (c) provided that the in-vitro dissolution profiles of your proposed 
product are comparable to those of the reference product. 

Dissolution test method and sampling times: 
Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 

1 Drug Efficacy Study Implementation 

Finalized Oct 2011 


